These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 24685434)

  • 1. Metabolic syndrome as a marker for prostate cancer: still a work in progress.
    Gallina A; Nini A; Montorsi F; Briganti A
    Eur Urol; 2015 Jan; 67(1):71-72. PubMed ID: 24685434
    [No Abstract]   [Full Text] [Related]  

  • 2. Words of wisdom. Re: Dissecting the association between metabolic syndrome and prostate cancer risk: analysis of a large clinical cohort.
    Damiano R; Cicione A; Cantiello F
    Eur Urol; 2015 May; 67(5):972-3. PubMed ID: 25845958
    [No Abstract]   [Full Text] [Related]  

  • 3. Dissecting the association between metabolic syndrome and prostate cancer risk: analysis of a large clinical cohort.
    Bhindi B; Locke J; Alibhai SMH; Kulkarni GS; Margel DS; Hamilton RJ; Finelli A; Trachtenberg J; Zlotta AR; Toi A; Hersey KM; Evans A; van der Kwast TH; Fleshner NE
    Eur Urol; 2015 Jan; 67(1):64-70. PubMed ID: 24568896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lifestyles, health habits, and prostate cancer.
    Kawada T
    J Cancer Res Clin Oncol; 2020 Jun; 146(6):1623-1624. PubMed ID: 30790052
    [No Abstract]   [Full Text] [Related]  

  • 5. Metabolic Syndrome and Aggressive Prostate Cancer at Initial Diagnosis.
    Di Francesco S; Tenaglia RL
    Horm Metab Res; 2017 Jul; 49(7):507-509. PubMed ID: 28494504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meta-analysis of metabolic syndrome and prostate cancer.
    Gacci M; Russo GI; De Nunzio C; Sebastianelli A; Salvi M; Vignozzi L; Tubaro A; Morgia G; Serni S
    Prostate Cancer Prostatic Dis; 2017 Jun; 20(2):146-155. PubMed ID: 28220805
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic syndrome, inflammation and lower urinary tract symptoms: possible translational links.
    He Q; Wang Z; Liu G; Daneshgari F; MacLennan GT; Gupta S
    Prostate Cancer Prostatic Dis; 2016 Mar; 19(1):7-13. PubMed ID: 26391088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Common medications and prostate cancer : what is the association ?].
    Rakauskas A; Grilo N; M'Baya O; Jichlinski P; Valerio M; Berthold D
    Rev Med Suisse; 2016 Nov; 12(541):2068-2071. PubMed ID: 28700151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reply to: Comment to: The association of metabolic syndrome and its components with serum prostate-specific antigen levels.
    Cumhur Cure M; Cure E
    Eur J Cancer Prev; 2021 Jan; 30(1):122. PubMed ID: 33273208
    [No Abstract]   [Full Text] [Related]  

  • 10. Role of Metabolic Syndrome in Prostate Cancer Development.
    Lifshitz K; Ber Y; Margel D
    Eur Urol Focus; 2021 May; 7(3):508-512. PubMed ID: 33994167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statin use and risk of prostate cancer in a population of men who underwent biopsy.
    Tan N; Klein EA; Li J; Moussa AS; Jones JS
    J Urol; 2011 Jul; 186(1):86-90. PubMed ID: 21571344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can histological inflammation detected in a repeat prostate biopsy predict the risk of prostate cancer?
    Dell'atti L
    Minerva Urol Nefrol; 2016 Oct; 68(5):462-4. PubMed ID: 27643655
    [No Abstract]   [Full Text] [Related]  

  • 13. Prostate biopsies should be performed according to a standard of care.
    Bartoletti R; Cai T
    Eur Urol; 2013 Mar; 63(3):528-9. PubMed ID: 22795518
    [No Abstract]   [Full Text] [Related]  

  • 14. The incidence of transition zone prostate cancer diagnosed by transperineal template-guided mapping biopsy: implications for treatment planning.
    Patel V; Merrick GS; Allen ZA; Andreini H; Taubenslag W; Singh S; Butler WM; Adamovich E; Bittner N
    Urology; 2011 May; 77(5):1148-52. PubMed ID: 21334045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Actual lowering effect of metabolic syndrome on serum prostate-specific antigen levels is partly concealed by enlarged prostate: results from a large-scale population-based study.
    Zhao S; Xia M; Tang J; Yan Y
    BJU Int; 2017 Oct; 120(4):482-489. PubMed ID: 27489082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate cancer with low PSA levels.
    Rocco B; Matei DV; de Cobelli O
    N Engl J Med; 2004 Oct; 351(17):1802-3. PubMed ID: 15499671
    [No Abstract]   [Full Text] [Related]  

  • 17. Do all patients with high-grade prostatic intraepithelial neoplasia on initial prostatic biopsy eventually progress to clinical prostate cancer?
    Sofikerim M; Tatlisen A; Karacagil M
    BJU Int; 2006 Apr; 97(4):869-70. PubMed ID: 16536793
    [No Abstract]   [Full Text] [Related]  

  • 18. Study of latent carcinoma of the prostate by step section technique.
    Ratanchandani GT; Chaphekar PM
    Indian J Cancer; 1972 Jun; 9(2):112-20. PubMed ID: 4635902
    [No Abstract]   [Full Text] [Related]  

  • 19. Metabolic syndrome diagnosis and widespread high grade prostatic intraepithelial neoplasia significantly increase prostate cancer risk: results from a multicenter biopsy study.
    Cicione A; De Nunzio C; Tubaro A; Cantiello F; Manno S; Oliveira C; Lima E; Damiano R
    BMC Cancer; 2016 Feb; 16():59. PubMed ID: 26846521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benign Prostatic Hyperplasia, Metabolic Syndrome and Non-Alcoholic Fatty Liver Disease: Is Metaflammation the Link?
    Russo GI; Cimino S; Castelli T; Favilla V; Gacci M; Carini M; Condorelli RA; La Vignera S; Calogero AE; Motta F; Puzzo L; Caltabiano R; Morgia G
    Prostate; 2016 Dec; 76(16):1528-1535. PubMed ID: 27458062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.